Related Experiment Video

Updated: Jun 4, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Obesity paradox in elderly patients with cardiovascular diseases

Thomas E Dorner1, Anita Rieder

  • 1Institute of Social Medicine, Center for Public Health, Medical University of Vienna, Vienna, Austria. thomas.dorner@meduniwien.ac.at

International Journal of Cardiology
|February 25, 2011
PubMed

Insights

The obesity paradox in cardiovascular disease (CVD) suggests higher BMI may lower mortality in elderly patients. However, body composition and individualized weight management are key for improving function and quality of life.

Area of Science:

  • Gerontology
  • Cardiology
  • Obesity Research

Background:

  • Cardiovascular diseases (CVD) disproportionately affect the elderly.
  • The
  • obesity paradox
  • suggests higher Body Mass Index (BMI) is linked to lower mortality in elderly CVD patients, but causality is debated.
  • Aging, obesity, CVD, frailty, and inflammation are interconnected and actively researched.

Purpose of the Study:

  • To explore the relationship between obesity and survival in elderly individuals with CVD.
  • To investigate the significance of body composition over BMI in this demographic.
  • To evaluate the impact of weight management strategies on elderly CVD patients' health outcomes.

Main Methods:

  • Review of existing studies on BMI, mortality, and elderly populations with CVD.
  • Analysis of the role of body composition (fat mass, fat-free mass) versus BMI.
  • Examination of data on weight loss interventions in obese elderly individuals with CVD.

Main Results:

  • Body composition metrics are more significant than BMI for elderly individuals.
  • Intentional weight reduction in obese elderly CVD patients can improve cardiovascular risk profiles and reduce inflammation.
  • Weight management focused on functional improvement and quality of life is crucial.

Conclusions:

  • The
  • obesity paradox
  • in elderly CVD patients requires further investigation beyond BMI.
  • Weight management strategies should be individualized, considering patient participation, comorbidities, functional status, and social support.
  • Focusing on physical function and quality of life is paramount for elderly CVD patients undergoing weight management.

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...